TMED vs. CANC

Last updated Jul 14, 2026

TMED (T. Rowe Price Health Care ETF) and CANC (Tema Oncology ETF) are both Health & Biotech Equities funds. Over the past year, TMED returned 39.05% vs 58.70% for CANC. A 0.77 correlation means they provide meaningful diversification when combined. TMED charges 0.44%/yr vs 0.75%/yr for CANC.

Performance

TMED vs. CANC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in T. Rowe Price Health Care ETF (TMED) and Tema Oncology ETF (CANC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TMED achieves a 16.84% return, which is significantly lower than CANC's 17.91% return.

TMED

• 1D: -0.28%
• 1M: 9.47%
• 6M: 14.05%
• YTD: 16.84%
• 1Y: 39.05%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CANC

• 1D: -1.73%
• 1M: 9.22%
• 6M: 13.62%
• YTD: 17.91%
• 1Y: 58.70%
• 3Y*: 104.11%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

TMED vs. CANC - Yearly Performance Comparison

	2026 (YTD)	2025
TMED T. Rowe Price Health Care ETF	16.84%	19.49%
CANC Tema Oncology ETF	17.91%	34.65%

Correlation

The correlation between TMED and CANC is 0.79, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.79
Correlation (All Time) Calculated using the full available price history since Jun 12, 2025	0.77

The correlation between TMED and CANC has been stable across timeframes, ranging from 0.77 to 0.79 - a consistent structural relationship.

Return for Risk

TMED vs. CANC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TMED

TMED Risk / Return Rank: 82
TMED Sharpe Ratio Rank: 84
TMED Sortino Ratio Rank: 86
TMED Omega Ratio Rank: 78
TMED Calmar Ratio Rank: 83
TMED Martin Ratio Rank: 79

CANC

CANC Risk / Return Rank: 92
CANC Sharpe Ratio Rank: 93
CANC Sortino Ratio Rank: 92
CANC Omega Ratio Rank: 86
CANC Calmar Ratio Rank: 95
CANC Martin Ratio Rank: 92

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TMED vs. CANC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for T. Rowe Price Health Care ETF (TMED) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	TMED	CANC	Difference
Sharpe ratio: Return per unit of total volatility	2.13	2.60	-0.47
Sortino ratio: Return per unit of downside risk	3.08	3.62	-0.54
Omega ratio: Gain probability vs. loss probability	1.37	1.41	-0.05
Calmar ratio: Return relative to maximum drawdown	3.53	6.34	-2.81
Martin ratio: Return relative to average drawdown	11.87	17.26	-5.39

TMED vs. CANC - Sharpe Ratio Comparison

The current TMED Sharpe Ratio is 2.13, which is comparable to the CANC Sharpe Ratio of 2.60. The chart below compares the historical Sharpe Ratios of TMED and CANC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

TMED vs. CANC - Drawdown Comparison

The maximum TMED drawdown since its inception was -11.11%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for TMED and CANC.

Drawdown Indicators

	TMED	CANC	Difference
Max Drawdown Largest peak-to-trough decline	-11.11%	-97.53%	+86.42%
Max Drawdown (1Y) Largest decline over 1 year	-11.11%	-9.30%	-1.81%
Max Drawdown (3Y) Largest decline over 3 years	—	-30.27%	—
Current Drawdown Current decline from peak	-1.86%	-51.12%	+49.26%
Average Drawdown Average peak-to-trough decline	-2.38%	-72.70%	+70.32%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.30%	3.41%	-0.11%

Volatility

TMED vs. CANC - Volatility Comparison

The current volatility for T. Rowe Price Health Care ETF (TMED) is 4.78%, while Tema Oncology ETF (CANC) has a volatility of 6.48%. This indicates that TMED experiences smaller price fluctuations and is considered to be less risky than CANC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TMED	CANC	Difference
Volatility (1M) Calculated over the trailing 1-month period	4.78%	6.48%	-1.70%
Volatility (6M) Calculated over the trailing 6-month period	14.06%	16.50%	-2.44%
Volatility (1Y) Calculated over the trailing 1-year period	18.50%	22.78%	-4.28%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	18.18%	277.14%	-258.96%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.18%	277.14%	-258.96%

TMED vs. CANC - Expense Ratio Comparison

TMED has a 0.44% expense ratio, which is lower than CANC's 0.75% expense ratio.

Dividends

TMED vs. CANC - Dividend Comparison

TMED's dividend yield for the trailing twelve months is around 0.47%, more than CANC's 0.05% yield.

Position	TTM	2025	2024	2023
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%
TMED T. Rowe Price Health Care ETF	0.47%	0.54%	0.00%	0.00%

Frequently Asked Questions

Can I hold both TMED and CANC in my portfolio?

TMED and CANC have a correlation of 0.79, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TMED or CANC?

CANC has higher volatility (6.48%) compared to TMED (4.78%). In terms of maximum drawdown, TMED dropped -11.11% vs CANC's -97.53%.

Which ETF is better, TMED or CANC?

On 1-year performance, CANC leads with 58.70% vs 39.05% for TMED. On fees, TMED is cheaper at 0.44% per year. On volatility, TMED has been the lower-risk option at 4.78%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, TMED or CANC?

Over the 1-year period, CANC has performed better with a 58.70% return vs 39.05%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, TMED or CANC?

TMED is cheaper with a 0.44% expense ratio, compared with 0.75% for CANC.

Which ETF pays a higher dividend yield, TMED or CANC?

TMED has the higher dividend yield at 0.47%, compared with 0.05% for CANC.

What is the main difference between TMED and CANC?

They also come from different issuers: T. Rowe Price and Tema. Their fees differ too: 0.44% for TMED and 0.75% for CANC.

Which has better risk-adjusted returns?

CANC currently has the higher Sharpe Ratio (2.60 vs 2.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.